Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy

Pharmacogenomics

Volumn 11, Issue 11, 2010, Pages 1525-1534

  Grover, Sandeep ^a   Talwar, Puneet ^a   Gourie Devi, Mandaville ^b   Gupta, Meenal ^a   Bala, Kiran ^b   Sharma, Sangeeta ^b   Baghel, Ruchi ^a   Kaur, Harpreet ^a   Sharma, Abhay ^a   Kukreti, Ritushree ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b INSTITUTE OF HUMAN BEHAVIOUR AND ALLIED SCIENCES   (India)

Author keywords

CYP1A1; estradiol; estrogen metabolizing pathway; first line antiepileptic drugs; neuropsychiatric disorders

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450 1A; ESTRADIOL; ESTROGEN; PHENOBARBITAL; PHENYTOIN; SEX HORMONE; VALPROIC ACID;

ARTICLE; DISEASE PREDISPOSITION; DRUG RESPONSE; EPILEPSY; EXON; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENT DISEASE; SEIZURE; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TONIC CLONIC SEIZURE;

EID: 78649706984     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.120     Document Type: Article

References (46)

1. Woolley CS: Acute effects of estrogen on neuronal physiology. Annu. Rev. Pharmacol. Toxicol. 47, 657-680 (2007).
2. McEwen BS, Alves SE: Estrogen actions in the central nervous system. Endocr. Rev. 20, 279-307 (1999).
3. Lurie G, Maskarinec G, Kaaks R, Stanczyk FZ, Le Marchand L: Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol. Biomarkers Prev. 14, 1521-1527 (2005).
4. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY: Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59, 4870-4875 (1999).
5. Klein P, Van Passel-Clark LM, Pezzullo JC: Onset of epilepsy at the time of menarche. Neurology 60, 495-497 (2003).
6. Harden CL, Koppel BS, Herzog AG, Nikolov BG, Hauser WA: Seizure frequency is associated with age at menopause in women with epilepsy. Neurology 61, 451-455 (2003).
7. Backstrom T: Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neuro. Scand. 54, 321-347 (1976).
8. Reddy DS: The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Res. 85, 1-30 (2009).
9. Herzog AG: Hormonal therapies: progesterone. Neurotherapeutics 6, 383-391 (2009).
10. Herzog AG, Harden CL, Liporace J et al.: Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann. Neurol. 56, 431-434 (2004).
11. Woolley CS, McEwen BS: Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J. Neurosci. 14, 7680-7687 (1994).
12. Hu M, Watson CJ, Kennedy RT, Becker JB: Estradiol attenuates the K+-induced increase in extracellular GABA in rat striatum. Synapse 59, 122-124 (2006).
13. McEwen B: Estrogen actions throughout the brain. Recent Prog. Horm. Res. 57, 357-384 (2002).
14. Scharfman HE: BDNF and epilepsy: a missing link- Epilepsy Curr. 5, 83-88 (2005).
15. Wise PM: Estradiol: a protective factor in the adult brain. J. Pediatr. Endocrinol. Metab. 13, 1425-1429 (2000).
16. Weiland NG: Glutamic acid decarboxylase messenger ribonucleic acid is regulated by estradiol and progesterone in the hippocampus. Endocrinology 131, 2697-2702 (1992).
17. Ledoux VA : Estradiol facilitates the release of neuropeptide-Y to suppress hippocampus-dependent seizures. J. Neurosci. 29, 1457-1468 (2009).
18. Zhu BT, Conney AH: Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19, 1-27 (1998).
19. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT: Characterization of the oxidative metabolites of 17b-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. Endocrinology 144, 3382-3398 (2003).
20. Spink DC, Eugster HP, Lincoln DW et al.: 17 b-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch. Biochem. Biophys. 293, 342-348 (1992).
21. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR: 17 b-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl Acad. Sci. USA 93, 9776-9781 (1996).
22. Dutheil F, Beaune P, Loriot MA: Xenobiotic metabolizing enzymes in the central nervous system: contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie 90, 426-436 (2008).
23. Ball P, Knuppen R: Formation of 2- and 4-hydroxyestrogens by brain, pituitary, and liver of the human fetus. J. Clin. Endocrinol. Metab. 47, 732-737 (1978).
24. Van Aswegen CH, Purdy RH, Wittliff JL: Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. J. Steroid Biochem. 32, 485-492 (1989).
25. Swaneck GE, Fishman J: Covalent binding of the endogenous estrogen 16 a-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc. Natl Acad. Sci. USA 85, 7831-7835 (1988).
26. Schutze N, Vollmer G, Tiemann I, Geiger M, Knuppen R: Catecholestrogens are MCF-7 cell estrogen receptor agonists. J. Steroid Biochem. Mol. Biol. 46, 781-789 (1993).
27. Roy D, Weisz J, Liehr JG: The O-methylation of 4-hydroxyestradiol is inhibited by 2-hydroxyestradiol: implications for estrogen-induced carcinogenesis. Carcinogenesis 11, 459-462 (1990).
28. Proposal for revised classifcation of epilepsies and epileptic syndromes: Commission on Classifcation and Terminology of the International League Against Epilepsy. Epilepsia 30(4), 389-399 (1989).
29. Grover S, Bala K, Sharma S et al.: Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie. 92(9), 1207-1212 (2010).
30. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215 (1988).
31. Pritchard JK, Rosenberg NA: Use of unlinked genetic markers to detect population stratifcation in association studies. Am. J. Hum. Genet. 65, 220-228 (1999).
32. Ruigrok YM, Seitz U, Wolterink S, Rinkel GJ, Wijmenga C, Urban Z: Association of polymorphisms and haplotypes in the elastin gene in Dutch patients with sporadic aneurysmal subarachnoid haemorrhage. Stroke 35, 2064-2068 (2004).
33. Gordon D, Finch SJ, Nothnagel M, Ott J: Power and sample size calculations for case-control genetic association tests when errors are present: application to single nucleotide polymorphisms. Hum. Hered. 54, 22-33 (2002).
34. Gordon D, Levenstien MA, Finch SJ, Ott J: Errors and linkage disequilibrium interact multiplicatively when computing sample sizes for genetic case-control association studies. Pac. Symp. Biocomput. 490-501 (2003).
35. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: ana lysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
36. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978-989 (2001).
37. Stephens M, Donnelly P: A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73, 1162-1169 (2003).
38. Conde L, Vaquerizas JM, Dopazo H et al.: PupaSuite: fnding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res. 34, W621-W625 (2006).
39. Kel AE, Gossling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, Wingender E: MATCH: a tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res. 31, 3576-3579 (2003).
40. Scharfman HE, MacLusky NJ: The infuence of gonadal hormones on neuronal excitability, seizures, and epilepsy in the female. Epilepsia 47, 1423-1440 (2006).
41. Sowers MR, Wilson AL, Kardia SR, Chu J, McConnell DS: CYP1A1 and CYP1B1 polymorphisms and their association with estradiol and estrogen metabolites in women who are premenopausal and perimenopausal. Am. J. Med. 119, S44-S51 (2006).
42. Crandall CJ, Sehl ME, Crawford SL et al.: Sex steroid metabolism polymorphisms and mammographic density in pre- and early peri-menopausal women. Breast Cancer Res. 11, R51 (2009).
43. Kravitz HM, Janssen I, Lotrich FE, Kado DM, Bromberger JT: Sex steroid hormone gene polymorphisms and depressive symptoms in women at midlife. Am. J. Med. 119, S87-S93 (2006).
44. Crandall CJ, Crawford SL, Gold EB: Vasomotor symptom prevalence is associated with polymorphisms in sex steroid-metabolizing enzymes and receptors. Am. J. Med. 119, S52-S60 (2006).
45. Kisselev P, Schunck WH, Roots I, Schwarz D: Association of CYP1A1 polymorphisms with differential metabolic activation of 17b-estradiol and estrone. Cancer Res. 65, 2972-2978 (2005).
46. Veliskova J: Estrogens and epilepsy: why are we so excited- Neuroscientist 13, 77-88 (2007).